211 related articles for article (PubMed ID: 21816044)
1. Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial).
Eckes J; Schmah O; Siebers JW; Groh U; Zschiedrich S; Rautenberg B; Hasenburg A; Jansen M; Hug MJ; Winkler K; Pütz G
BMC Cancer; 2011 Aug; 11():337. PubMed ID: 21816044
[TBL] [Abstract][Full Text] [Related]
2. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
[TBL] [Abstract][Full Text] [Related]
3. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
[TBL] [Abstract][Full Text] [Related]
4. Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer.
Kubeček O; Martínková J; Chládek J; Bláha M; Maláková J; Hodek M; Špaček J; Filip S
Cancer Chemother Pharmacol; 2020 Feb; 85(2):353-365. PubMed ID: 31728628
[TBL] [Abstract][Full Text] [Related]
5. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
[TBL] [Abstract][Full Text] [Related]
6. Controlled application and removal of liposomal therapeutics: effective elimination of pegylated liposomal doxorubicin by double-filtration plasmapheresis in vitro.
Pütz G; Schmah O; Eckes J; Hug MJ; Winkler K
J Clin Apher; 2010; 25(2):54-62. PubMed ID: 20222030
[TBL] [Abstract][Full Text] [Related]
7. Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing.
Ngoune R; Contini C; Hoffmann MM; von Elverfeldt D; Winkler K; Putz G
Curr Drug Deliv; 2018; 15(9):1261-1270. PubMed ID: 29779479
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
9. Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view.
Blaha M; Martinkova J; Lanska M; Filip S; Malakova J; Kubecek O; Bezouska J; Spacek J
Atheroscler Suppl; 2017 Nov; 30():286-293. PubMed ID: 29096853
[TBL] [Abstract][Full Text] [Related]
10. Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients.
Kubeček O; Bláha M; Diaz-Garcia D; Filip S
Acta Medica (Hradec Kralove); 2015; 58(1):3-8. PubMed ID: 26454800
[TBL] [Abstract][Full Text] [Related]
11. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
[TBL] [Abstract][Full Text] [Related]
12. Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.
Giovinazzo H; Kumar P; Sheikh A; Brooks KM; Ivanovic M; Walsh M; Caron WP; Kowalsky RJ; Song G; Whitlow A; Clarke-Pearson DL; Brewster WR; Van Le L; Zamboni BA; Bae-Jump V; Gehrig PA; Zamboni WC
Cancer Chemother Pharmacol; 2016 Mar; 77(3):565-73. PubMed ID: 26822231
[TBL] [Abstract][Full Text] [Related]
13. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.
Alba E; Ruiz-Borrego M; Margelí M; Rodríguez-Lescure A; Sánchez-Rovira P; Ruiz A; Mel-Lorenzo JR; Ramos-Vázquez M; Ribelles N; Calvo E; Casado A; Márquez A; Vicente D; García-Sáenz JA; Martín M
Breast Cancer Res Treat; 2010 Jul; 122(1):169-76. PubMed ID: 20361253
[TBL] [Abstract][Full Text] [Related]
14. Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial.
Herzog TJ; Kutarska E; Bidzińsk M; Symanowski J; Nguyen B; Rangwala RA; Naumann RW
Int J Gynecol Cancer; 2016 Nov; 26(9):1580-1585. PubMed ID: 27654255
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and its relation to toxicity of pegylated-liposomal doxorubicin in Chinese patients with breast tumours.
Xu L; Wang W; Sheng YC; Zheng QS
J Clin Pharm Ther; 2010 Oct; 35(5):593-601. PubMed ID: 20831683
[TBL] [Abstract][Full Text] [Related]
16. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
17. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
[TBL] [Abstract][Full Text] [Related]
18. [Safety of PLD in the treatment of the patients with recurrent ovarian cancer--clinical experience].
Malkowska-Walczak B; Nowak-Markwitz E; Spaczyński M
Ginekol Pol; 2009 Sep; 80(9):682-6. PubMed ID: 19886242
[TBL] [Abstract][Full Text] [Related]
19. Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer.
Yao J; Pan S; Fan X; Jiang X; Yang Y; Jin J; Liu Y
J Chemother; 2020 Jul; 32(4):202-207. PubMed ID: 32281493
[TBL] [Abstract][Full Text] [Related]
20. Reduction in skin and mucosal toxicity with pegylated liposomal doxorubicin utilizing every 2-week dosing.
Rose PG; Purpura D; Petersen L
Anticancer Drugs; 2019 Jul; 30(6):636-639. PubMed ID: 30973518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
